Avisi Technologies has secured $10.7 million in new funding from investors. The company is focused on developing a portfolio of ophthalmic treatments utilizing a novel metamaterial technology. Its primary product, VisiPlate, is a nanotechnology-enabled implant designed to treat glaucoma, a condition recognized as the leading cause of irreversible blindness globally for which there is currently no cure. This investment marks a significant milestone for Avisi as it advances its mission to address critical unmet needs in eye care.
The newly raised capital will be strategically deployed to accelerate the research and development of Avisi's innovative treatments. Specifically, the funds will support the continued progression of VisiPlate through its development stages, aiming to bring this potential solution closer to patients suffering from glaucoma. This funding round underscores investor confidence in Avisi's unique technological approach and its potential to revolutionize ophthalmic care.
Avisi Technologies has previously received support from venture investors, alongside grants and awards from institutions such as the National Science Foundation and the University of Pennsylvania. The company has also been recognized with prestigious accolades, including the Glaucoma Research Foundation H. Dunbar Hoskins International Innovations Award and the Ophthalmology Technology Summit People’s Choice Award, highlighting its innovative contributions to the medical technology landscape.
Looking ahead, Avisi Technologies plans to leverage this investment to expand its scientific and operational capabilities. The company is committed to advancing its pipeline of ophthalmic solutions, with the ultimate goal of delivering effective treatments that can significantly improve patient outcomes and combat the devastating effects of irreversible blindness caused by conditions like glaucoma.
.png&w=3840&q=75)
